Juno Therapeutics (JUNO) Stock Rating Lowered by SunTrust Banks

A statistical measure of the dispersion of returns (volatility) for JUNO producing salvation in Investors mouth, it has week volatility of 6.20% and for the month booked as 4.89%. Considering that the gene-editing pioneer's CRISPR technology could enable more efficient immunotherapies, Wall Street is correctly identifying that the two companies' wagons are hitched - to a certain extent, anyway.

In the pre-market trade, JUNO is trading at $86.05, up $18.24 or 26.90%. About 16.76M shares traded or 492.18% up from the average. Their average price target spell out an upbeat performance - a -13% and would give JUNO a market capitalization of almost $7.06B. It has underperformed by 56.55% the S&P500. Trading volume for Juno Therapeutics Inc. was 35.99 Million in its previous trading session.

Biopharmaceutical giant Celgene will purchase Juno Therapeutics for $9 billion in a move to expand in the increasingly competitive cancer treatment landscape, reports Bloomberg.

Whereas they predicted High and Low Earnings Estimate as $-0.59 and $-1.59 respectively. Therefore 44% are positive. (NASDAQ:JUNO) opened at 28.78 on Friday. The rating was maintained by Morgan Stanley on Monday, August 7 with "Equal-Weight". The Motley Fool recommends Editas Medicine and Juno Therapeutics. Recently, analysts have updated the overall rating to 2.2. Wedbush initiated it with "Neutral" rating and $24.0 target in Thursday, February 2 report. The firm earned "Sell" rating on Thursday, June 8 by BTIG Research. The company was spun out of big biotech Biogen Inc. past year after Biogen couldn't find any companies willing to buy it for about $3 billion, according to a person familiar with the matter. At present, 0 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. On Wednesday, July 22 the stock rating was initiated by Northland Capital with "Outperform".

Celgene already owns a little under 10% of Juno and has collaborated with the CAR-T specialist since 2015, when they signed a 10-year collaboration to develop treatments for cancer and immune diseases, but will now take complete control of JCAR017-in phase 1 for non-Hodgkin's lymphoma-as well as eight additional clinical and preclinical projects. Regulatory approval for JCAR017 in the U.S.is expected in 2019 with potential global peak sales of approximately $3 billion.

In June 2015, Celgene collaborated with Juno to develop medicines for patients with cancer and autoimmune diseases with a primary focus on auto T and TCR technologies.

Investors sentiment increased to 1.44 in 2017 Q3. Given that earnings are what matter most to investors, analysts tend to place a greater weight on the P/E. JUNO's free cash flow ("FCF") per share for the trailing twelve months was -0.51. Iguana Healthcare Mgmt Ltd reported 75,000 shares.

How Active Are Juno Therapeutics, Inc.

The stock of Juno Therapeutics Incorporated (NASDAQ:JUNO) registered a decrease of 1.83% in short interest. Bioverativ's stock will be bought for $105 per share in cash - a 64% premium to Friday's closing price. Knott David M invested in 0.01% or 529 shares.

Celgene has had an estimated $500 million stake in Juno since September, according to a report from Jefferies. The Motley Fool owns shares of and recommends Celgene. Ancora, a Us-based fund reported 5,000 shares.

The company's stock is now moving with a +ve distance from the 200 day SMA of approximately 129.6%, and has a solid year to date (YTD) performance of 88.14% which means that the stock is constantly adding to its value from the previous fiscal year end price.

  • Zachary Reyes